|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Laparoscopic management of intra-abdominal infections:Systematic review of the literature显示文摘AIM: To investigate the role of laparoscopy in diagnosis and treatment of intra abdominal infections.METHODS: A systematic review of the literature was performed including studies where intra abdominal infections were treated laparoscopically.RESULTS: Early laparoscopic approaches have become the standard surgical technique for treating acute cholecystitis. The laparoscopic appendectomy has been demonstrated to be superior to open surgery in acute appendicitis. In the event of diverticulitis, laparoscopic resections have proven to be safe and effective procedures for experienced laparoscopic surgeons and may be performed without adversely affecting morbidity and mortality rates. However laparoscopic resection has not been accepted by the medical community as the primary treatment of choice. In high-risk patients, laparoscopic approach may be used for exploration or peritoneal lavage and drainage. The successful laparoscopic repair of perforated peptic ulcers for experienced surgeons, is demonstrated to be safe and effective. Regarding small bowel perforations, comparative studies contrasting open and laparoscopic surgeries have not yet been conducted. Successful laparoscopic resections addressing iatrogenic colonic perforation have been reported despite a lack of literature-based evidence supporting such procedures. In post-operative infections, laparoscopic approaches may be useful in preventing diagnostic delay and controllingthe source.CONCLUSION: Laparoscopy has a good diagnostic accuracy and enables to better identify the causative pathology; laparoscopy may be recommended for the treatment of many intra-abdominal infections. | Federico Coccolini Cristian Tranà Massimo Sartelli Fausto Catena Salomone Di Saverio Roberto Manfredi Giulia Montori Marco Ceresoli Chiara Falcone Luca Ansaloni | 2015 | World Journal of Gastrointestinal Surgery2015，7，8： | 5 |
| 2 | Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review显示文摘Despite advances in the management of patients with locally advanced,non-metastatic rectal adenocarcinoma(LARC),prognosis remains largely unsatisfactory due to a high rate of distant relapse.In fact,currently available neoadjuvant protocols,represented by fluoropyrimidine-based chemo-radiotherapy(CT-RT)or short-course RT,together with improved surgical techniques,have largely reduced the risk of local relapse,with limited impact on distant recurrence.Available results of phaseⅢtrials with additional cytotoxic agents combined with standard CT-RT are disappointing,as no significant reduction in the risk of recurrence has been demonstrated.In order to improve the control of micrometastatic disease,integrating targeted agents into neoadjuvant treatment protocols thus offers a rational approach.In particular,the antiangiogenic agent bevacizumab has demonstrated synergistic activity with both CT and RT in pre-clinical and clinical models,and thusmay represent a suitable companion in the neoadjuvant treatment of LARC.Preliminary results of phase?Ⅰ-Ⅱclinical studies are promising and suggest potential clinical parameters and molecular predictive biomarkers useful for patient selection:treatment personalization is indeed the key in order to maximize the benefit while reducing the risk of more complex neoadjuvant treatment schedules. | Lorenzo Fornaro Chiara Caparello Caterina Vivaldi Virginia Rotella Gianna Musettini Alfredo Falcone Editta Baldini Gianluca Masi | 2014 | World Journal of Gastroenterology2014，20，20： | 5 |
| 3 | FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer显示文摘Pancreatic cancer is an extremely aggressive disease; although progress has been made in the last few years, the prognosis of these patients remains dismal. FOLFIRINOX is now considered a standard treatment in first-line setting, since it demonstrated an improved overall and progression-free survival vs gemcitabine alone. However, the enthusiasm over the benefit of this three-drug regimen is tempered by the associated increased toxicity profile, and many efforts have been made to improve the feasibility of this schedule. After a more recent phase Ⅲ trial showing an improved outcome over gemcitabine, the combination of gemcitabine/nab-paclitaxel emerged as another standard first-line treatment. However, this treatment is also associated with more side effects. In addition, despite initial promising data on the predictive role of SPARClevels, recent studies showed that these levels are not associated with nab-paclitaxel efficacy. The choice to use this treatment over FOLFIRINOX is therefore a topic of debate, also because no validated biomarkers to guide FOLFIRINOX treatment are available. In the era of actionable mutations and target agents it would be desirable to identify molecular factors or biomarkers to predict response to therapy in order to maximize the efficacy of treatment and avoid useless toxic effects for non-responding patients. However, until today the milestone of treatment for pancreatic cancer remains chemotherapy combinations, without predictive or monitoring tools existing to optimize therapy. This review analyzes the state-of-the-art treatments, promises and limitations of targeted therapies, ongoing trials and future perspectives, including potential role of microR NAs as predictive biomarkers. | Chiara Caparello Laura L Meijer Ingrid Garajova Alfredo Falcone Tessa Y Le Large Niccola Funel Geert Kazemier Godefridus J Peters Enrico Vasile Elisa Giovannetti | 2016 | World Journal of Gastroenterology2016，22，31： | 4 |
| 4 | Hepatitis C virus and GBV‐C virus prevalence among patients with B‐cell lymphoma in different European regions: a case‐control study of the International Extranodal Lymphoma Study Group显示文摘 | Sabrina Nicolosi Guidicelli Armando Lopez‐Guillermo Umberto Falcone Annarita Conconi Alexandre Christinat Delvys Rodriguez‐Abreu Salvatore Grisanti Chiara Lobetti‐Bodoni Jean Claude Piffaretti Peter W. Johnson Giorgio Mombelli Andreas Cerny Emili Montserr | 2011 | Hematol Oncol2011，，3： | 1 |
| 5 | Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma显示文摘 | Michele Cavo Lucia Pantani Maria Teresa Petrucci Francesca Patriarca Elena Zamagni Daniela Donnarumma Claudia Crippa Mario Boccadoro Giulia Perrone Antonietta Falcone Chiara Nozzoli Renato Zambello Luciano Masini Anna Furlan Annamaria Brioli Daniele Derud | 2012 | Blood2012，，1： | 1 |
| 6 | Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma显示文摘 | Michele Cavo Lucia Pantani Maria Teresa Petrucci Francesca Patriarca Elena Zamagni Daniela Donnarumma Claudia Crippa Mario Boccadoro Giulia Perrone Antonietta Falcone Chiara Nozzoli Renato Zambello Luciano Masini Anna Furlan Annamaria Brioli Daniele Derud | 2012 | Blood2012，，1： | 1 |
| 7 | Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients显示文摘 | Bruno Vincenzi Alice Zoccoli Gaia Schiavon Michele Iuliani Francesco Pantano Emanuela Dell’Aquila Raffaele Ratta Andrea Onetti Muda Giuseppe Perrone Chiara Brunelli Pierpaolo Correale Elisabetta Riva Antonio Russo Fotios Loupakis Alfredo Falcone Daniele S | 2012 | European Journal of Cancer2012，，： | 1 |
| 8 | New therapeutic perspectives in Type 1 Diabetes: dietary interventions prevent β cell-autoimmunity by modifying the gut metabolic environment显示文摘The gut microbiota plays a key role in the pathogenesis of autoimmune diseases such as Type 1 Diabetes(T1D),but the mechanism underlying this modulation is yet to be defined.This paper highlights the crucial role of the microbiota-induced gut metabolic profile,rather than the presence of single bacterial strains,in T1D modulation.Most importantly,it provides the first evidence that dietary interventions can modulate the autoimmune pathogenesis of T1D by altering the gut metabolic environment. | Chiara Sorini Ilaria Cosorich Marika Falcone | 2017 | Cellular & Molecular Immunology2017，14，12： | 1 |
| 9 | Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial显示文摘 | Stefano Cascinu Rossana Berardi Roberto Labianca Salvatore Siena Alfredo Falcone Enrico Aitini Sandro Barni Francesco Di Costanzo Elisa Dapretto Giuseppe Tonini Chiara Pierantoni Salvatore Artale Silvia Rota Irene Floriani Mario Scartozzi Alberto Zaniboni | 2008 | Lancet Oncology2008，，1： | 1 |
| 10 | Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy显示文摘 | Lorenzo Fornaro Caterina Vivaldi Chiara Caparello Rodolfo Sacco Virginia Rotella Gianna Musettini Sauro Luchi Edi Editta Baldini Alfredo Falcone Gianluca Masi | 2014 | Future Oncol2014，，2： | 1 |
| 11 | Colorectal cancer stem cells properties and features:evidence of interleukin-8 involvement显示文摘Colorectal cancer(CRC)still remains a disease with high percentage of death,principally due to therapy resistance and metastasis.During the time the hypothesis has been reinforced that CRC stem cells(CRCSC)are involved in allowing intratumoral heterogeneity,drug escape mechanisms and secondary tumors.CRCSC are characterized by specific surface markers(i.e.,CD44 and CD133),signaling pathways activation(i.e.,Wnt and Notch)and gene expression(i.e.,Oct4 and Snail),which confer to CRCSC self-renewal abilities and pluripotent capacity.Interleukin(IL)-8 is correlated to CRC progression,development of liver metastases and chemoresistance;moreover,IL-8 modulates not only stemness maintenance but also stemness promotion,such as epithelial-mesenchymal transition.This review wants to give a brief and up-to-date overview on IL-8 implication in CRCSC cues. | Fabiana Conciatori Chiara Bazzichetto Italia Falcone Gianluigi Ferretti Francesco Cognetti Michele Milella Ludovica Ciuffreda | 2019 | Cancer Drug Resistance2019，2，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员